Jan 2018


To help address the uncertainty that many doctors are facing about whether, what or how to prescribe cannabis medicines the NSW Government has launched the country’s first cannabis medicines hotline. In an effort to fast-track patient access the NSW Cannabis Medicines Advisory Service will provide doctors with timely, high-quality clinical advice.

The hotline – part of a $21 million investment in cannabis medicines research – will simplify and speed up access for doctors whose patients may benefit from this type of treatment.

NSW Chief Health Officer Dr Kerry Chant said doctors anywhere in NSW can ring the hotline for guidance from leading clinicians in this emerging area of medicine.

The Service will provide guidance for the use of cannabis medicines, including advice on clinical management, available medicines, and dosage information. The Service will also provide advice on symptom relief for palliative care patients.

“The Service will also have access to tests to help doctors monitor their patient’s progress whilst using cannabis medicines,” Dr Chant said.

“This information, together with findings from our clinical trials program, will accelerate our knowledge and understanding about the role of cannabis medicines and inform future practice.”

The Advisory Service is based at Hunter New England Health and is working with the Australian Centre for Cannabinoid Clinical and Research Excellence, based at the University of Newcastle.


NSW Cannabis Medicines Advisory Hotline for doctors and health professionals: (02) 4923 620

We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.


We have successfully passed three consecutive TGO93 and TGO100 tests on our medicinal cannabis products since our first commercial harvest at the end of 2019.


One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.


We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.